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 Abstract 
 
The association of long QT syndrome and left ventricular noncompaction is 
uncommon, with only a handful of previous reports, and only one reported case in 
association with a mutation in KCNQ1. Here we present genetic and phenotypic data 
for 4 family members across 2 generations who all have evidence of prolonged QT 
interval and left ventricular noncompaction in association with a pathogenic mutation 
in KCNQ1, and discuss the potential mechanisms of this association.  In conclusion, 
we suggest that it may be helpful to consider looking for mutations in KCNQ1 in 
similar patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
 
Long QT syndrome (LQTS) encompasses a group of disorders characterised by 
mutations affecting ion channels in the myocardium, leading to prolongation of the 
QT interval and risk of torsades de pointes arrhythmia and ventricular fibrillation. 15 
subtypes (LQT1-15) have been delineated, with KCNQ1 (LQT1), KCNH2 (LQT2) 
and SCN5A (LQT3) being the most commonly identified.  Although arrhythmic 
syndromes are classically considered to be genetically distinct to hereditary 
cardiomyopathies, some phenotypic overlap has been reported previously.  For 
example, mutations in SCN5A, which is classically associated with LQT3 and 
Brugada syndrome, have been found in patients with arrhythmic DCM. (1) A recent 
study looking at echocardiographic findings in patients with LQT gene mutations 
demonstrated that in 20%, subclinical cardiomyopathic changes were found, and this 
correlated with prolonged QT interval on ECG and history of arrhythmic events. (2) A 
further study has also demonstrated subtly reduced systolic and diastolic function in 
patients with LQTS compared to controls, again suggesting that LQTS may not purely 
be an electrical disease. (3)  There have also been a handful of case reports of patients 
with both long QT syndrome and left ventricular noncompaction; this appears to be a 
rare association.  Left ventricular noncompaction (LVNC) is defined as a congenital 
cardiomyopathy with increased trabeculation along with deep intertrabecular recesses 
of the myocardium, and can be associated with arrhythmia, cardiac failure and 
thromboembolism.  Diagnosis is confirmed by imaging, usually cardiac MRI, looking 
for a specific ratio of noncompacted to compacted myocardium (>2.3). (4, 5, 6, 7) 
Diagnosis can be complicated by the fact that trabeculation can occur as a 
physiological trait.  For example, this can be seen in as a normal variant in athletes, 
and is most likely due to increased left ventricle preload and afterload. (8) LVNC can 
be sporadic or familial, and appears to be genetically heterogeneous.  Mutations in 
tafazzin have been detected in children with LVNC (9); other genes, which have been 
linked to LVNC, include SCN5A (10), LMNA, MYH7, MYBPC3 (11), KCNQ1 (12), 
KCNH2 (13) and HCN4 (14, 15), but more work is needed to confirm the significance 
of these.  It can be isolated, or occur with other features, such as congenital heart 
defects or neuromuscular disorders, such as myotubular myopathy.  It can also occur 
as part of a syndrome, examples being Turner syndrome, 1p36 deletion syndrome and 
22q11.2 deletion syndrome. (8) Here, we describe a pedigree in which 3 siblings have 
been found to have long QT syndrome and evidence of LVNC with a LQT1-
associated KCNQ1 mutation. 
 
Materials and Methods 
 
PCR amplification of KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A was followed 
by PCR clean up using Agencourt AMPure XP magnetic beads on a on a Biomek 
NXp lab automation workstation as per manufacturer’s instructions. 1µl of the 
cleaned up PCR product was used with ABI BigDye Terminator v3.1 sequencing kit. 
The sequencing reactions products were cleaned up using Agencourt CleanSEQ 
magnetic beads on a on a Biomek NXp lab automation workstation as per 
manufacturer’s instructions and analysed on an ABI 3730 genetic analyser. The 
sequencing results were analysed using Mutation Surveyor software (current version 
5.0.0) from SoftGenetics.    
 
The complete coding regions and flanking intronic sequences of the MYBPC3 
(NM_000256.3), MYH7 (NM_000257.2), TNNT2 (NM_000364.2), TNNI3 
(NM_000363.4), TPM1 (NM_001018005.1), MYL2 (NM_000432.3) genes were 
amplified by PCR using 10x ReddyMix PCR buffer (Thermo Scientific). PCR 
products were cleaned up using Agencourt AMPure XP (Beckman Coulter). Products 
were sequenced bidirectionally using fluorescent Big Dye v3.1 (Life Technologies) 
and cleaned up using CleanSEQ (Beckman Coulter). Sequencing products were run 
on the ABI 3130 and sequencing data analysed using Mutation Surveyor software 
v4.0.8 (Softgenetics). 
 
A multiplex PCR primer panel for the major cardiac muscle isoform (NM_003319.4) 
of the Titin (TTN) gene was created using the Ion AmpliseqTM Designer tool 
(www.ampliseq.com). This panel (IAD25063) predicts coverage of >99.7% of the 
coding and flanking intronic regions (+2, -2) of the TTN gene. Target enrichment 
(library construction) for TTN was performed using the Titin custom design primers 
and Ion Ampliseq library kit v2.0 (Life Technologies). Emulsion PCR and enrichment 
was subsequently carried out using the Ion OneTouch 2 instrument (200bp template 
kit) and Ion ES module. Sequencing was carried out on an Ion Torrent Personal 
Genome Machine (Ion PGM Sequencing 200 kit v2). All stages of the workflow were 
carried out according to the manufacturer’s instructions. >95% of the coding sequence 
and flanking intronic sequences of major cardiac muscle isoform (N2-B) of TTN were 
covered to a minimum depth of 20 reads.  Sequence data was mapped and variants 
identified using Variant Caller (Torrent Suite Software) and NextGENe (Softgenetics) 
with hg19 (GRCh37) human genome as the reference. 
 
Case Report 
 
The proband, III6, was a 48-year-old gentleman from a Caucasian, non-
consanguineous family (Figure 1).  He initially presented with atypical chest pain. He 
had no history of any medical problems, apart from a possible hole in the heart as a 
child. The resting ECG was found to be abnormal, showing sinus rhythm with 
inferolateral T wave inversion as well as a long QT interval (QTc 471ms) (Figure 2). 
Echocardiography showed appearances suggestive of a healed perimembraneous 
ventricular septal defect and hypertrabeculation at the apex associated with 
hypokinesia, an ejection fraction of 45-47% and reduced longitudinal function (Figure 
3).  Subsequent MRI confirmed the noncompaction. Due to the combination of 
abnormal findings on the ECG and echocardiogram, he was thought to have LVNC.  
He was advised to contact his first-degree relatives so that they could be screened 
clinically. 
 
His sister, III4, was then reviewed.  She was found to have a prolonged QT interval 
(QTc 506ms) (Figure 4) and cardiac MRI showed an area of hypertrabeculation of the 
apical inferolateral wall, although this did not meet the diagnostic criteria for LVNC. 
(Figure 5) She also had mitral valve prolapse.  DNA samples were taken, with 
sarcomere gene testing (MYBPC3, MYH7, TNNT2, TNNI3, TPM1 and MYL2) carried 
out initially, which did not detect any mutations.  TTN was also tested, with no 
mutations detected.  In view of the prolonged QT interval, channelopathy genes were 
screened as well (KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A).  A c.817C>T 
(p.L273F) mutation in KCNQ1 was detected, which has been previously reported in 
LQT1 (16). Her 2 adult sons have been tested and have not inherited this gene change; 
they both have normal echocardiograms and ECGs. 
 
Another sibling, III1, was also reviewed.  She was found to have a prolonged QT 
interval (QTc 507ms) (Figure 6) and cardiac MRI showed apical hypertrabeculation 
consistent with LVNC (Figure 7).  She was subsequently tested to see if she had the 
same mutation in KCNQ1 as her sister, which was the case. The proband was then 
tested and also found to have the KCNQ1 mutation.  His children have also been 
assessed, one of whom (IV8) has a prolonged QT interval (QTc 520ms).  
Echocardiogram showed trabeculation of the apex of the left ventricle consistent with 
LVNC in the context of excellent ventricular function, and she has subsequently been 
found to have the familial KCNQ1 mutation.   No evidence of skeletal myopathy was 
found in any members of the family, and none of them are known to regularly 
participate in sporting activity except IV8, who dances regularly.  The clinical and 
genetic findings in each of these patients are summarised in Table 1. 
  
Discussion 
 
LVNC is a relatively recently established cardiomyopathy. It was first described in 
1984 and is frequently associated with arrhythmia.  A study by Shan et al looking at 
the frequency of SCN5A mutations in patients with LVNC showed that those with an 
associated arrhythmia were more likely to have a SCN5A mutation (50% in 
arrhythmia group compared to 7% in control group, p= 0.0003). These patients had a 
variety of arrhythmias, with 2/17 having long QT syndrome. (10) 
 
As mentioned, there are a number of conditions and genes associated with LVNC, 
suggesting that it may be a consequence of a variety of disease processes.   It may 
well be that abnormal ionic current flow seen in LQTS is one of these processes, 
although the association of LVNC and LQTS appears to be uncommon.  This may be 
due to the fact that it is not necessarily looked for by imaging in LQT cases, or that it 
truly is a rare association.   Several cases have been reported in association with 
mutations in ion channel genes.  Along with the 2 cases reported by Shan et al, there 
have also been 2 cases reported by Ogawa et al with LVNC and long QT syndrome, 
who both have different mutations in KCNH2. (13) Recent reports have associated 
LVNC and bradycardia with HCN4 mutations in multiple families. (14, 15)  
 
Only 1 other case associated with KCNQ1 mutation has been reported so far.  
Nakashima et al reported the case of a 5-year-old girl who suffered a cardiac arrest 
and was found to have LVNC and long QT syndrome.  She was found to have a 
previously reported pathogenic mutation in KCNQ1 (c.1831G>T, D611Y), in the C 
terminus region.  Several members of her family were found to carry this mutation, 
but none of them had ECG or echocardiographic abnormalities detected. (12) 
 
The mutation in our pedigree lies in a distinct region of the KCNQ1 channel protein, 
the S5 transmembrane domain.  The L273F mutation is causally linked to LQT1. (16) 
Functional cardiac “IKs” (slow delayed rectifier) potassium channels are formed by 
coassembly of KCNQ1 with KCNE1; KCNQ1+KCNE1 channels lack the marked 
current inactivation that is present for KCNQ1 alone. For the L273F mutant KCNQ1, 
KCNE1 coexpression is no longer able to eliminate KCNQ1 inactivation, and this is 
expected to limit repolarizing current flow through native IKs channels. (17)   
 Work has been undertaken to look at therapeutic options that could activate IKs  
channels and so overcome KCNQ1 inactivation, although there is no such agonist 
currently available for clinical use.  For example, zinc pyrithione (ZnPy) has been 
found to augment current and reduce inactivation in experiments on recombinant 
KCNQ1 channels, though it does not augment recombinant KCNQ1+KCNE1 or 
native IKs (18) A small molecule activator of IKs called ML277 may have more 
promise.  Using patient specific stem-cell derived myocytes, ML277 has been shown 
to increase IKs in cells with reduced IKs from LQT1 patients. (19)  Thus, this 
compound or future derivatives may have potential for some LQT1 patients.  Gene 
therapy would involve replacement of defective KCNQ1 with KCNQ1 lacking the 
L273F mutation. Were such treatment possible in an adult, this would likely correct 
the LQT phenotype, but whether or not it could alter established LVNC is open to 
question, due to the stage of development at which this occurs.   
 
Looking at embryonic mouse models, expression of KCNQ1 mRNA and protein has 
been found to commence at embryonic day 9.5 (E9.5).  It appears to be evenly 
expressed within the atrial and ventricular myocardium, including the trabeculated 
layer, from E9.5 to E18.5.  After this time, it appears to be preferentially expressed in 
the conducting system. (20)  Formation of trabeculae occurs at E9.5-10.5, followed by 
elongation and then compaction of the trabecular myocardium at E14.5-E18.5. (21) 
This suggests that, in mice, KCNQ1 channels are expressed at the same time as 
formation and compaction of the trabeculae occurs, so the channels could conceivably 
play a role in this process, but more work is needed to characterise the possible 
underlying mechanism.   
 Since all four affected family members with both long QT syndrome and evidence of 
LVNC have the KCNQ1 mutation and the two relatives who tested negative have 
neither long QT nor LVNC, this suggests that as well as causing the long QT 
syndrome, the mutation may also be important in the development of LVNC.  
However, it is possible there could actually be 2 separate conditions which are co-
segregating in this family.  There is a 1/32 chance that this could have happened by 
chance.  Alternatively, there may be a second genetic alteration in the family that is 
linked due to its proximity to KCNQ1 on the chromosome.  
 
As IV8 has been found to be clinically affected and carries the familial KCNQ1 
mutation, this suggests autosomal dominant inheritance in the family.  A possible 
mechanism in view of this is that there may be a genetic modifier acting in 
conjunction with the KCNQ1 mutation to cause LVNC along with long QT syndrome.  
For example, there could be a further variant in KCNQ1 in trans or a concurrent 
mutation of another gene.  More work needs to be done to understand how changes in 
KCNQ1 could lead to LVNC.  It is notable that a recent report has linked a KCNQ1 
mutation (p.R397Q) with arrhythmogenic cardiomyopathy, although the underlying 
mechanism remains to be established (22).  This report highlights 4 familial cases of 
long QT syndrome and LVNC across 2 generations, all of which have a pathogenic 
KCNQ1 mutation, and illustrates the importance of considering testing for KCNQ1 
mutations in these patients, especially in the context of long QT or arrhythmia. 
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Legend 1 
Pedigree diagram.  Members with LQT and LVNC are shaded in black, and mutation 
status is demonstrated by +/- annotation. 
 
Legend 2 
Echocardiographic images of patient III6 demonstrating hypertrabeculation. 
 Legend 3 
ECG of patient III6 demonstrating prolonged QT interval (512ms). 
 
Legend 4  
MRI images of patient III4 demonstrating hypertrabeculation. 
 
Legend 5 
ECG of patient III4 demonstrating prolonged QT interval (506ms). 
 
Legend 6 
MRI images of patient III1 demonstrating left ventricular noncompaction. 
 
Legend 7 
ECG of patient III1 demonstrating prolonged QT interval (507ms). 
 
Table 1 
Summary of ECG and imaging findings in all family members tested for the familial 
KCNQ1 mutation 







 Family 
member 
ECG findings Imaging findings KCNQ1 
mutation 
III1 Prolonged QT 
interval – QTc 
507ms 
Apical 
hypertrabeculation 
+ 
III4 Prolonged QT 
interval – QTc 
506ms 
Hypertrabeculation 
apical inferolateral 
wall 
+ 
III6 Prolonged QT 
interval – QTc 
471ms 
Apical 
hypertrabeculation 
+ 
IV8 Prolonged QT 
interval – 520ms 
Apical 
hypertrabeculation 
+ 
IV5 Normal Normal - 
IV6 Normal Normal - 
 
